非小细胞肺癌共存驱动基因变异的克隆结构与生存影响
该研究分析了5420例非小细胞肺癌病例,发现共存驱动突变占3.9%,KRAS是最常见共存驱动基因(67%),KRAS+PIK3CA组合最常见(35%)。KRAS与EGFR共存突变在早期和晚期均与更差的总生存相关,而KRAS+PIK3CA或EGFR+PIK3CA共存仅在晚期与更差预后相关。
要点
- 共存驱动突变见于3.9%的NSCLC,女性比例更高,KRAS是最常见共存驱动基因。
- KRAS+EGFR共存突变在早期和晚期均与更差总生存相关。
- KRAS+PIK3CA或EGFR+PIK3CA共存仅在晚期与更差预后相关。
核心结论
- 驱动突变在NSCLC各阶段均可共存,并对预后有显著影响。
- 全面基因组检测包括共存变异对有效治疗管理很重要。
研究设计与样本
- 回顾性分析QEII Health Sciences Centre的5420例NSCLC病例,评估主要驱动变异并分析临床和生存数据。
主要发现
- KRAS突变最常见,其次为EGFR,女性变异频率更高。
- 共存驱动突变占3.9%,女性比例更高;KRAS是最常见共存驱动(67%),KRAS+PIK3CA组合最常见(35%)。
- 57.3%的共存变异肿瘤至少有一个可靶向变异。
- 克隆性分析显示KRAS和EGFR为主要起始驱动,PIK3CA、AKT1和IDH1多为继发事件。
- KRAS+EGFR共存突变较KRAS单突变总生存更差:早期HR 2.58(95%CI 1.45-13.05,p=0.0091),晚期HR 3.23(95%CI 2.27-18.60,p=0.0008);较EGFR单突变亦更差:早期HR 4.14(95%CI 1.99-23.27,p=0.0025),晚期HR 3.37(95%CI 2.50-20.75,p=0.0006)。
临床怎么用
- 对NSCLC患者进行包含共存变异的全面基因组检测,以指导治疗决策和预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coexisting driver mutations in non-small cell lung cancer (NSCLC) can influence tumor biology, therapeutic response, and patient outcomes, yet these implications remain underexplored. METHODS: 5420 NSCLC cases from QEII Health Sciences Centre were analyzed. Major driver variants were assessed, and clinical and survival data were analyzed. RESULTS: KRAS mutations were the most common variants, followed by EGFR, with higher variant frequency found in females. Coexisting driver mutations were found in 3.9% of tumors analyzed, with higher proportion in females. KRAS was the most frequent co-mutated driver (67%), and the most common combination of coexisting mutations was KRAS and PIK3CA (35%). 57.3% of tumors with coexisting alterations had at least one actionable variant. Clonality analysis demonstrated KRAS and EGFR as major initiating drivers, while PIK3CA, AKT1 and IDH1 were mostly secondary events. EGFR + KRAS mutations were associated with worse overall survival compared to patients with KRAS mutations only, in both early (HR: 2.58, 95% CI [1.45-13.05], p = 0.0091) as well as advanced-stage cohorts (HR: 3.23, 95% CI [2.27-18.60], p = 0.0008). Similar outcomes were observed compared to EGFR mutations in early (HR: 4.14, 95% CI [1.99-23.27], p = 0.0025) and advanced-stage cohorts (HR: 3.37, 95% CI [2.50-20.75], p = 0.0006). However, presence of KRAS + PIK3CA or EGFR + PIK3CA co-mutations did not impact prognosis in early-stage but was associated with worse outcomes in advanced-stage. CONCLUSION: Driver mutations coexist in NSCLC at various stages and can have a significant impact on prognosis. Comprehensive genomic profiling, investigating all oncogenic alterations including coexisting variants, is important for effective therapeutic management.
引用
- Shah R, Pathak GP, Fris J, et al. Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression. Eur J Cancer. 2026. PMID: 42456541. doi:10.1016/j.ejca.2026.116936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。